% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • toowan12 toowan12 Nov 20, 2012 6:47 AM Flag

    SGI 110 gets oral dose of good news at ASH

    From abstract:

    "Conclusions: SGI-110 is well tolerated at doses higher than BED which is established at 60 mg/m2 dailyx5 where average hypomethylation of ~25% was achieved. MTD estimated to be 90 mg/m2 dailyx5 for MDS and 125 mg/m2dailyx5 for AML patients. SQ administration of SGI-110 achieved efficient conversion to decitabine resulting in an improved PK profile over DAC IV. Clinical responses were observed in this heavily pretreated population and they seem to correlate with the extent of LINE-1 hypomethylation. Study is currently enrolling patients in the dose-expansion Phase 2 stage.

    Supported by a grant from Stand Up To Cancer "